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SCIENTIFIC EDITORIAL
Cardiac  biomarkers  in  patients  suspected  of
acute  myocardial  infarction:  Where  do  we
stand  and  where  do  we  go?
Biomarqueurs  chez  les  patients  suspects  d’infarctus  du
myocarde  ;  où  sommes-nous  et  dans  quelle  direction  aller  ?
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One  year  ago,  in  this  journal,  I questioned  whether  by  using  the  actual  biomarker  (mainly
sensitive  cardiac  troponin  [cTn]  assays)  we  were  close  to  reaching  the  Holy  Grail  [1]  —  and
I  thought  we  were.  In  fact,  major  advances  in  the  ﬁeld  of  biomarkers  have  occurred  in  the
past  few  years:  cTn  assays  have  been  reﬁned,  making  it  possible  to  measure  and  quantify
small  cardiomyocyte  injury  and  to  determine  the  99th  percentile  of  a  reference  population
with  high  precision.  Everyone  was,  therefore,  able  to  conform  to  the  third  universal  deﬁ-
nition  of  acute  myocardial  infarction  (AMI)  [2]. In  addition,  evidence  existed  that  the  use
of  sensitive  cTn  assays  instead  of  contemporary  assays  improved  the  detection  of  patients
with  AMI  [3],  and  that  the  change  in  the  management  of  these  patients  facilitated  by  these
sensitive  assays  made  a  clinically  signiﬁcant  difference  [4].
Instead  of  there  being  a  rapid  and  broad  consensus  about  the  use  of  these  sensitive
or  high-sensitivity  cTn  assays  (hs-cTn),  and  an  optimal  protocol  to  recommend,  importantMarqueur  biologique  ;
Infarctus  du  myocarde
uncertainties  were  raised  about  their  clinical  value,  the  threshold  value  to  use  in  routine
practice,  the  optimal  timing  of  serial  measurements,  and  the  possible  need  for  a  reﬁnement
of  our  classiﬁcation  of  acute  coronary  syndrome.  These  questions  are  not  yet  fully  resolved
and  some  experts  are  already  recommending  that  we  rely  on  a  combination  of  biomarkers.
Abbreviations: AMI, acute myocardial infarction; cTn, cardiac troponin; hs-cTn, high-sensitivity cTn.
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While  most  cTn  assays  used  in  Europe  are  sensitive  or
s-cTn  assays,  conventional  cTn  assays  are  still  in  use  in
he  USA.  Although  the  European  Society  of  Cardiology,  the
merican  Heart  Association  and  the  American  College  of
ardiology  have  endorsed  the  third  universal  deﬁnition  of
MI,  many  institutions  and  physicians  continue  to  use  higher
ut-off  values  for  cTn  than  the  99th  percentile,  arguing  that
he  99th  percentile  has  very  low  speciﬁcity,  especially  in  the
lderly.  This  is  correct,  but  I  also  think  that  encouraging  such
n  attitude  is  of  major  concern,  as  it  will  inevitably  lower
he  performance  of  the  assay  and  possibly  harm  patients
5,6].  As  the  99th  percentile  has  been  recently  conﬁrmed  in
arge  studies  of  unselected  patients  as  the  optimal  threshold
alue,  whatever  the  time  from  onset  of  chest  pain  to  presen-
ation  [7],  it  ought  to  be  used.  However,  the  99th  percentile
ight  be  slightly  different  (more  elevated)  in  some  very  spe-
iﬁc  populations.  At  least  two  studies  focused  on  elderly
atients,  and  suggested  that  the  99th  percentile  may  be
igher  in  this  group  than  in  a  generally  younger  population;
his  is  particularly  relevant  for  patients  aged  over  80  years
8,9].  In  a  recent  study,  our  group  reported  that  advanced
ge  was  more  related  to  hs-cTn  concentrations  than  to  renal
ailure  [8],  but  this  study  excluded  patients  with  end-stage
enal  failure.  One  should,  however,  keep  in  mind  that  using
oo  low  a  cut-off  value  will  not  alter  the  rule-out  procedure,
ut  will  only  reinforce  the  need  for  a  second  measurement,
nd  that  the  presence/absence  of  a  signiﬁcant  rise/fall  will
elp  to  differentiate  AMI  from  other  causes  of  chest  pain
10].
I  assume  that  we  will  progressively  rely  more  and  more
n  biomarkers,  without  omitting  clinical  evaluation  and  the
lectrocardiogram  to  estimate  the  pretest  probability.  A
ood  goal  might  be  not  only  to  rule  out  AMI  but  also  to
e  able  to  rule  out  any  severe  cardiac  conditions.  To  opti-
ize  cost  and  resources,  we  should  move  to  new  algorithms
hat  allow  both  a  rule-out  and  a  rule-in  decision.  Whether
e  will  be  able  to  draw  a  conclusion  using  a  single  marker
easured  twice  or  will  need  to  measure  a  combination  of
iomarkers  is  unknown  as  yet.  Reichlin  et  al.  [11]  suggested
he  ﬁrst  hypothesis,  as  they  demonstrated  the  ability  to
olve  the  problem  adequately  using  a  1-hour  protocol.  This  is
ery  encouraging,  but  needs  conﬁrmation;  their  results  have
ust  been  conﬁrmed  by  the  High-Sensitivity  Cardiac  Troponin
 Assay  for  Rapid  Rule  Out  of  Acute  Myocardial  Infarction
TRAPID-AMI)  study  [12].
Measuring  a  second  biomarker  that  reﬂects  cardiomy-
cyte  damage,  endogenous  stress  or  even  plaque  rupture
ight  be  very  challenging.  Recent  studies  have  demon-
trated  that  markers  of  plaque  rupture  and/or  inﬂammation
re  not  helpful  when  added  to  the  actual  standard  of
are  [13].  Thus,  copeptin  is  the  marker  that  provides  most
ope  today.  Copeptin  is  a  marker  of  endogenous  stress,
nd  previous  studies  have  demonstrated  that  endogenous
tress  and  myocyte  damage/necrosis  are  reciprocal.  The
iomarkers  in  Cardiology-8  (BIC-8)  study  was  a  random-
zed  study  that  demonstrated  that  a  combination  of  cTn
nd  copeptin  measured  at  presentation  was  not  inferior  to
Tn  alone  (but  measured  twice),  and  allowed  more  patients
o  be  discharged  safely  [14].  This  study  had  important
imitations,  including  a  lower  than  anticipated  number  of
bserved  events  and  the  combination  of  conventional  and
s-cTn  assays.  While  being  very  meaningful,  the  resultsC.  Meune  et  al.
f  this  study  have  to  be  conﬁrmed  in  a dedicated  study
hat  uses  the  actual  optimal  standard  of  care  (i.e.  hs-cTn
ssays).
Lastly,  but  importantly,  will  these  new  markers/protocols
orce  us  to  reﬁne  our  classiﬁcation  of  acute  coronary  syn-
rome,  and  should  this  limit  their  broad  use?  From  a
heoretical  point  of  view,  the  condition  named  unstable
ngina  may  not  disappear.  However,  the  new  hs-cTn  assays
llow  the  reclassiﬁcation  of  patients  who  were  previously
lassiﬁed  as  having  unstable  angina  to  AMI  [15].  These  sen-
itive  assays  also  allow  the  identiﬁcation  of  three  categories
f  patients  with  acute  chest  pain:  those  at  high  risk  of  events
uring  a  short  follow-up  period  (patients  with  AMI);  those
t  very  low  risk  (patients  in  a  stable  condition,  possibly
ith  chronic  angina);  and  those  at  low  risk  during  a  short
ollow-up  period,  but  at  higher  risk  if  the  follow-up  period
s  prolonged  [16]. Whether  we  should  go  on  labelling  these
onditions  as  unstable  angina  is  unknown  as  yet.  However,
he  possible  reﬁnement  of  the  old  classiﬁcation  should  not
ead  to  a reluctance  to  use  the  new  deﬁnitions.
To  conclude,  sensitive  cTn  assays  carried  out  at  presen-
ation  and  repeated  after  3  hours  are  the  actual  standard  of
are,  and  their  use  (including  the  99th  percentile  as  the  cut-
ff  value)  has  to  be  encouraged.  More  rapid  protocols  will
merge  soon,  and  will  be  the  strategies  of  the  future—with
r  without  the  additional  use  of  copeptin.  Whether  we  will
ave  to  consider  a  speciﬁc  cut-off  value  for  very  elderly
atients  remains  unknown.
isclosure of interest
rofessor  Meune  has  received  research  grant  support  from
rahms  and  Roche  Diagnosis,  and  lecture  fees  from  Roche
iagnosis.
Linda  Aïssou  and  Emmanuel  Sorbets  declare  that  they
ave  no  conﬂicts  of  interest  concerning  this  article.
eferences
[1] Meune C, Goudot FX, Gobeaux-Chenevier C. New/actual car-
diac biomarkers in patients with suspected acute myocardial
infarction: are we close to identifying the ‘‘Holy Grail’’? Arch
Cardiovasc Dis 2012;105:541—3.
[2] Thygesen K, Alpert JS, Jaffe AS, et al. Third universal deﬁnition
of myocardial infarction. Circulation 2012;126:2020—35.
[3] Reichlin T, Irfan A, Twerenbold R, et al. Utility of absolute
and relative changes in cardiac troponin concentrations in
the early diagnosis of acute myocardial infarction. Circulation
2011;124:136—45.
[4] Mills NL, Churchhouse AM, Lee KK, et al. Implementation of
a sensitive troponin I assay and risk of recurrent myocardial
infarction and death in patients with suspected acute coronary
syndrome. JAMA 2011;305:1210—6.
[5] Meune C, Balmelli C, Twerenbold R, et al. Patients with acute
coronary syndrome and normal high-sensitivity troponin. Am J
Med 2011;124:1151—7.acute cardiac ischemia in the emergency department. N Engl
J Med 2000;342:1163—70.
[7] Meune C, Balmelli C, Vogler E, et al. Consideration of high-
sensitivity troponin values below the 99th percentile at
[[
[
[16] Meune C, Reichlin T, Irfan A, et al. How safe is the out-Cardiac  biomarkers  in  suspected  AMI  
presentation: does it improve diagnostic accuracy? Int J Cardiol
2013;168:3752—7.
[8] Menacer S, Claessens YE, Meune C, et al. Reference range
values of troponin measured by sensitive assays in elderly
patients without any cardiac signs/symptoms. Clin Chim Acta
2013;417:45—7.
[9] Reiter M, Twerenbold R, Reichlin T, et al. Early diagnosis of
acute myocardial infarction in the elderly using more sensitive
cardiac troponin assays. Eur Heart J 2011;32:1379—89.
[10] Haaf P, Drexler B, Reichlin T, et al. High-sensitivity cardiac
troponin in the distinction of acute myocardial infarction
from acute cardiac noncoronary artery disease. Circulation
2012;126:31—40.
[11] Reichlin T, Schindler C, Drexler B, et al. One-hour rule-out
and rule-in of acute myocardial infarction using high-sensitivity
cardiac troponin T. Arch Intern Med 2012;172:1211—8.
[12] Mueller C, Giannitsis E, Christ M, Ordonez-Llanos J, deFilippi
CR, et al. Prospective multicenter evaluation of a 1h-algorithm
in the diagnosis of myocardial infarction using high-sensitivity645
cardiac Troponin T. Eur Soc Cardiol 2014 [Vol. Registry hot line
presentation. Barcelona, Spain].
13] Schaub N, Reichlin T, Meune C, et al. Markers of plaque insta-
bility in the early diagnosis and risk stratiﬁcation of acute
myocardial infarction. Clin Chem 2012;58:246—56.
14] Mockel M, Searle J, Hamm C, et al. Early discharge using
single cardiac troponin and copeptin testing in patients with
suspected acute coronary syndrome (ACS): a randomized, con-
trolled clinical process study. Eur Heart J 2014.
15] Giannitsis E, Becker M, Kurz K, Hess G, Zdunek D, Katus HA.
High-sensitivity cardiac troponin T for early prediction of evolv-
ing non-ST-segment elevation myocardial infarction in patients
with suspected acute coronary syndrome and negative troponin
results on admission. Clin Chem 2010;56:642—50.patient management of patients with acute chest pain and
mildly increased cardiac troponin concentrations? Clin Chem
2012;58:916—24.
